Home > Publications

Publications

KILLING ME SOFTLY: PHARMA ACQUISITIONS AND COMPETITIVE HARM

In recent years, there has been growing concern that acquisitions in the pharmaceutical industry may have as their object or effect the discontinuation of overlapping drug R&D projects to the detriment of innovation competition and, ultimately, consumers. Such acquisitions are commonly referred to as ‘killer acquisitions’. Is it possible to determine which transactions in the pharmaceutical industry deserve closer scrutiny for a killer acquisition assessment, and what are the typical features of such transactions?

 

 


Date: January 2025
Author(s): Clarissa Lotti, Rossella Mossucca